- | SOTIO
Opportunities for CAR T-Cell Therapy in Solid Tumors
Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.
- | Anima Biotech
The Intersection of mRNA Biology and Artificial Intelligence is Yielding Unique mRNA Drug Candidates
Anima Biotech has developed a unique technology for monitoring protein synthesis in real time in the presence of small molecules.
- | SalioGen
The 9 Things Wildly Successful Biotechs Have in Common
“You can’t just have great scientists. You also need great managers and staff who will build culture,” Sung You, managing partner at PBM Capital and chief business officer at SalioGen Therapeutics, said.
- | SOTIO
Launching of Early-Phase Trial May Mark a ‘Major Milestone’ for Improving Gastric and Pancreatic Cancer Treatment
The first patient has been dosed in the ongoing phase 1/2 CLAUDIO-01 clinical trial examining a new antibody drug conjugate called SOT102 in patients with gastric and pancreatic cancer, according to SOTIO, the manufacturer of the drug.
- | Anixa
Episode 22-17 Stopping Breast Cancer Before It Starts? on Apple Podcasts
Dr. Amit Kumar, the President and CEO of Anixa Biosciences, about a new approach to actually preventing the truly aggressive triple negative breast cancer, and its potential for other breast cancers and ovarian cancer.
- | Windtree Therapeutics
Windtree is Bringing Patients Back from Cardiogenic Shock in Phase II
New data unveiled by Windtree Therapeutics shows significant promise in heart failure patients who have deteriorated into cardiogenic shock.
- | BlueSphere Bio
TCR Search-and-Capture: Working Toward Personalized Cancer Therapy
Cell and gene therapy is not immune to the personalized medicine trend, and BlueSphere Bio hopes its leading T-cell receptor engineering (TCR) platform, along with its TCX-101 clinical candidate, can ultimately bolster the armamentarium for patients with hematologic malignancies and solid tumors.
- | BlueSphere Bio
AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology
BlueSphere Bio, for example, is trying to improve the efficacy of allogeneic stem cell transplant (alloSCT) treatments for patients with hematologic malignancies and solid tumors using its T-cell receptor (TCR) discovery platform. That platform, TCXpress™, identifies TCRs that may be especially efficacious against some of the most challenging types of cancer.
